摘要
目的探讨利拉鲁肽联合达格列净治疗2型糖尿病(T2DM)的效果及安全性。方法抽取2019年1月至2021年9月晋城市人民医院收治的80例T2DM患者,按照随机数字表法分为对照组(38例)和观察组(42例)。两组患者均给予常规治疗,对照组在此基础给予达格列净治疗,观察组在对照组基础上联合利拉鲁肽治疗,连续治疗3个月。比较两组糖代谢指标[空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2hPBG)]、血脂指标[低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、三酰甘油(TG)、总胆固醇(TC)]、胰岛β细胞功能指标[空腹胰岛素(FIns)、胰岛素抵抗指数(HOMA-IR)],以及不良反应发生情况。结果治疗前,两组FBG、2hPBG、HbA1c水平比较差异未见统计学意义(P>0.05);治疗后,两组上述糖代谢指标均下降,且观察组低于对照组(P<0.05)。治疗前,两组血脂指标比较差异未见统计学意义(P>0.05);治疗后,两组LDL、TG、TC水平均升高,HDL水平下降,且观察组优于对照组(P<0.05)。治疗前,两组FIns、HOMA-IR比较差异未见统计学意义(P>0.05);治疗后,两组FIns升高,HOMA-IR下降,且观察组优于对照组(P<0.05)。观察组不良反应发生率(7.14%,3/42)与对照组(5.26%,2/38)比较差异未见统计学意义(P>0.05)。结论T2DM患者采用达格列净与利拉鲁肽联合疗法,可有效控制其血糖水平,明显改善血脂代谢及胰岛β细胞功能,且安全性良好。
Objective To investigate the efficacy and safety of liraglutide combined with dapagliflozin in the treatment of type 2 diabetes mellitus(T2DM).Methods A total of 80 patients with T2DM admitted to Jincheng People’s Hospital from January 2019 to September 2021 were selected,and divided into control group(n=38)and observation group(n=42)by random number table method.All patients were given routine treatment.On this basis,patients in the control group were treated with dapagliflozin,and patients in the observation group were treated with liraglutide base on th treatment of the control group.Both groups underwent 3 consecutive months of treatment.The two groups were compared on glucose metabolism indicators,including fasting blood glucose(FBG),glycated hemoglobin(HbA1c)and 2 hours postprandial blood glucose(2hPBG),blood lipids,including low density lipoprotein(LDL),high density lipoprotein(HDL),triacylglycerol(TG)and total cholesterol(TC),pancreaticβ-cell function indicators,including fasting insulin(FIns)and insulin resistance index(HOMA-IR),and adverse reactions.Results There was no statistically significant difference between the two groups in the levels of FBG,2hPBG and HbA1c before treatment(P>0.05);after treatment,the above glucose metabolism indicators were decreased in the two groups,and those indicators in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference between the two groups in blood lipids indexes before treatment(P>0.05);after treatment,the levels of LDL,TG and TC were increased,and the level of HDL was decreased in the two groups,and the observation group had better blood lipids indexes than the control group(P<0.05).There was no statistically significant difference between the two groups in FIns and HOMA-IR before treatment(P>0.05);after treatment,FIns was increased,and HOMA-IR was decreased in the two groups,and the two indicators in the observation group were better than those in the control group(P<0.05).There was no statist
作者
祁亚郁
李琴
Qi Yayu;Li Qin(Department of Endocrinology,Jincheng People’s Hospital,Jincheng 048026,China)
出处
《中国实用医刊》
2022年第20期101-104,共4页
Chinese Journal of Practical Medicine
关键词
2型糖尿病
利拉鲁肽
达格列净
血糖代谢、胰岛β细胞功能
安全性
Diabetes mellitus,type 2
Liraglutide
Dapagliflozin
Blood glucose metabolism,pancreaticβ-cell function
Safety
